Adoptive Immunotherapy of Ovarian Carcinoma

Gramont, Aimery de; Gangji, Diamon; Louvet, C.; Garcia, Marie‐Line; Tardy, D; Romet-Lemonne, Jean-Loup

doi:10.1006/gyno.2002.6667

Cited by 19 publications

(21 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peptide vaccines have been used so far to a lesser extent since they have some important limitations [136]. Although the development of a specific immune response could be shown in patients undergoing such approaches [137,138], the role of these approaches remains investigational.…”

Section: Cytokines Growth Factors and Association With Lymphocytes' mentioning

confidence: 99%

Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies

2009

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of cancer-related death among women. Disease relapse occurs in a high number of cases and treatment currently involves the use of chemotherapy with the use of paclitaxel and platinum-based agents. Resistance to the disease occurs in more than 70% of the cases. The immune system is increasingly becoming a target for intense research in order to study the host's immune response against ovarian cancer. T cell populations, including NK T cells and Tregs, have been associated with disease outcome indicating their increasing clinical significance, having been associated with positive prognosis and as markers of disease progress, respectively. Cytokines may also be associated with positive prognosis and they can have a direct or indirect effect in mobilizing relevant T cells, thus eliciting an immune response. Harnessing the immune system capacity in order to induce anti-tumor response is a major challenge. This is achieved via the use of antibodies that can elicit an immune response or via the use of direct administration of cytotoxic T cell populations (e.g., CD8?). This review examines the recent developments in our understanding of the mechanisms of development of the immune response in ovarian cancer as well as its prognostic significance and the existing experience in clinical studies using factors associated with immune response, such as monoclonal antibodies, cytokines, vaccines and activated or expanded relevant autologous populations from peripheral blood.

show abstract

Section: Cytokines Growth Factors and Association With Lymphocytes' mentioning

confidence: 99%

Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies

2009

View full text Add to dashboard Cite

show abstract

“…A combination of unconjugated Mabs combined with cytotoxic chemotherapy administration was assessed in four trials (43,47,53,57). Because of the high propensity to stay confined to the peritoneal cavity until very late in the course of the disease, many trials on radiolabeled Mab in ovarian cancer patients used the ip route for administration (19/44) (38,41,44,50,51,63,64,(66)(67)(68)(69)(70)(71)(73)(74)(75)(76)(77)(78). In 20 studies the Mab was administered iv (36,37,39,40,42,43,45-49,52-55,57,60,65,72,79), two studies injected im (59,61), while 2 other studies used both iv and ip routes of administration Table I.…”

Section: Clinical Trialsmentioning

confidence: 99%

“…Several trials demonstrated that MDX-H210 is well-tolerated and also immunologically active (96,97). De Gramont et al (44) combined monocyte-derived activated killer (MAK) cells with the bispecific Mab MDX-H210 in an attempt to direct the MAK killer effect in patients towards HER2 antigen expressing tumor cells. Patients with HER2 overexpression were treated with MAK cells and Mab MDX-H210 while HER2 negative patients only received MAK cells.…”

Section: ------------------------------------------------------------mentioning

confidence: 99%

“…Patients with HER2 overexpression were treated with MAK cells and Mab MDX-H210 while HER2 negative patients only received MAK cells. A total of 8 ovarian cancer patients in CCR with microscopic or macroscopic residual disease after debulking and chemotherapy received MAK cells combined with MDX-H210 (44). Of these 8 patients only 3 remained in CCR, while 4 patients had progressive disease and one patient had stable disease as diagnosed at third-look laparotomy.…”

Section: ------------------------------------------------------------mentioning

confidence: 99%

“…Of these 8 patients only 3 remained in CCR, while 4 patients had progressive disease and one patient had stable disease as diagnosed at third-look laparotomy. The full therapeutic potential of MAK cells as consolidation therapy in ovarian cancer is currently being evaluated in a large randomized, comparative trial (44).…”

Section: ------------------------------------------------------------mentioning

confidence: 99%

See 2 more Smart Citations

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Massuger¹,

Boerman²,

Thomas³

et al. 2008

Int J Oncol

View full text Add to dashboard Cite

Abstract.The prognosis for patients with ovarian cancer is still poor and more effective therapeutic modalities are needed. (Radio)immunotherapy using monoclonal antibodies (Mabs) could be one of these approaches. Here, we review the status of (radio)immunotherapy using Mabs for the treatment of ovarian cancer. The Pubmed database was searched for clinical trials investigating the effect of (radio)immunotherapy in ovarian cancer published until October 1, 2007. Keywords for the search were: ovarian cancer, monoclonal antibodies, CA 125, gp38, HER2, HMFG, MUC1, TAG 72 and VEGF. A total of 44 trials on immunotherapy with unconjugated Mabs, Mab vaccination and (radio)immunotherapy directed towards the antigens CA 125, gp38, HER2, MUC1, TAG 72 or VEGF in patients with ovarian cancer were found, reviewed and discussed. Out of these trials, 23 studied immunotherapy with unconjugated Mabs, 5 vaccination with Mabs and 16 trials studied (radio)immunotherapy. The lack of large randomized prospective trials with Mabs directed to tumor-associated antigens expressed on ovarian cancer cells preclude any firm conclusion on the potential of Mabs use in the treatment of ovarian cancer. Oregovomab, directed against CA 125, and bevacizumab, targeting VEGF, are two unconjugated Mabs closest to clinical introduction for the treatment of ovarian cancer. Vaccination with Mab ACA 125 seems promising but these findings need to be confirmed in controlled randomized trials. Sole RIT should be investigated with the appropriate radionuclide and a Mab with high affinity for the specific tumor-associated antigen in the appropriate patient group to determine whether it may have a therapeutic effect. Additionally, appending (radio)immunotherapy with anti-TAG 72 or anti-MUC1 to other treatment strategies such as chemotherapy could also be a strategy worthwhile investigating. The potential of Mabs to complement current treatment paradigms, is encouraging and may bring a significant improvement to the overall therapeutic outcomes currently being achieved in ovarian cancer. IntroductionOvarian cancer is the fourth leading cause of cancer-related death in women, and accounts for the highest mortality rate of all gynecological malignancies (1). Its poor prognosis is mainly the result of the clinically occult nature of this disease. The peritoneal cavity in which the ovaries are localized provides a perfect environment for undisturbed subclinical growth. Furthermore, early detection is difficult because of the general asymptomatic presentation of the disease (2). In the majority (68%) of the patients, ovarian cancer is diagnosed with at least extensive abdominal spread (3). Standard treatment for advanced stage ovarian cancer is tumor debulking surgery and adjuvant chemotherapy. Although most ovarian cancers are sensitive to platinumbased chemotherapy, the prognosis remains poor. The 5-year INTERNATIONAL JOURNAL OF ONCOLOGY 32: 1145-1157 The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (Review) Abbreviations: ADCC, anti...

show abstract

Trifunctional bispecific antibody–induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract

et al. 2005

View full text Add to dashboard Cite

show abstract

Adoptive Immunotherapy of Ovarian Carcinoma

Cited by 19 publications

References 3 publications

Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies

Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Trifunctional bispecific antibody–induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract

Contact Info

Product

Resources

About